Accessibility Menu
Aptevo Therapeutics logo

Aptevo Therapeutics(NASDAQ) APVO

Market Cap$5.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-100%
5 Year-100%
1 Year-92%
1 Month-8%
$4.00
+0.50%
+0.02Today
After hours$4.11+$0.11 (+2.78%)
Aptevo Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 4.112026-07-31
Aptevo Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.38%USD 4.392026-07-24
1 month-7.64%USD 4.452026-07-01
3 month-16.46%USD 4.922026-05-01
Year to date-56.42%USD 9.432025-12-31
1 year-91.82%USD 50.222025-07-31
3 year-100%USD 574,358.402023-08-01
5 year-100%USD 11,000,721.602021-07-30
Since inception-100%USD 23,707,957.342016-08-01

Aptevo Therapeutics Financials at a Glance

Market Cap

$5.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$26.26M

EPS (TTM)

-$203.74

P/E Ratio

-0.02

Dividend

$0.00

Beta (Volatility)

1.21 (Average)

Price

$4.00

Volume

10,339.173

Open

$4.07

Previous Close

$4.11

Daily Range

$4.07 - $4.11

52-Week Range

$3.68 - $50.40

Estimated Earnings Date

Aug 10, 2026

APVO News

Foolcom-Featured.png

Aptevo Reports 85% Remission in Q2

Motley Fool Markets TeamAug 11, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aptevo Therapeutics

Aptevo develops new medicines for cancer patients who need better treatment options. Its main products help the immune system find and attack cancer cells. These therapies aim to improve outcomes for people with hard-to-treat cancers.

Lab Bench to Bedside: Aptevo’s Main Offerings

  • Mipletamig (APVO436): Experimental drug for acute myelogenous leukemia, designed to help immune cells target cancer.
  • ALG.APV-527: Early-stage therapy for solid tumors, developed with Alligator Bioscience AB, aims to boost immune response against cancer.
  • APVO603: Preclinical drug targeting two immune system proteins, intended for various cancers.
  • APVO442: Early-stage therapy for prostate cancer, designed to improve drug delivery to tumors.
  • ADAPTIR and ADAPTIR-FLEX Platforms: Proprietary technologies for creating new cancer-fighting antibodies.

Growth Spurts and Strategic Moves

  • Formed partnership with Alligator Bioscience AB in 2017 to co-develop ALG.APV-527.
  • Expanded pipeline with new trispecific and bispecific drug candidates in 2024 and 2025.
  • Secured $60 million equity line facility in January 2026 to support operations.
  • Entered into two Standby Equity Purchase Agreements with Yorkville (2025, 2026) for additional funding.

What Makes Aptevo Stand Out

Aptevo owns unique platforms for designing multi-targeted cancer drugs. Its therapies focus on activating the immune system while aiming to reduce side effects. The company’s small size allows for focused research and quick adaptation to new findings.

Five Things You Need to Know

  • No product revenue reported for 2023, 2024, or 2025.
  • Net loss was $8 million in QQ3 2025, up 46% from QQ3 2024.
  • Cash and equivalents reached $10 million in QQ3 2025, up 209.2% year-over-year.
  • Research and development expenses were $14.5 million in 2025, up 0.7% from 2024.
  • Company relies on equity financing, with no significant debt as of December 2025.

Bottom Line

Aptevo remains a pre-revenue biotech focused on immune-based cancer therapies. Its future depends on clinical progress and continued access to funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

36

CEO

Marvin L. White, MBA

Website

www.aptevotherapeutics.com

Headquarters

Seattle, WA 98121, US

APVO Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-198.50%

Return on Capital

-119.55%

Return on Assets

-131.93%

Earnings Yield

-50.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.25M

Volume

10.34K

Avg. Volume

55.91K

Financials (TTM)

Gross Profit

-$116.00K

Operating Income

-$26.67M

EBITDA

-$26.04M

Operating Cash Flow

-$26.98M

Capital Expenditure

$0.00

Free Cash Flow

-$26.98M

Cash & ST Invst.

$14.53M

Total Debt

$4.42M

Aptevo Therapeutics Performance Analysis

Aptevo Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 3,114,000-74.7%
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Aptevo Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Aptevo Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 921,915.57N/A
20232023-12-31USD -834,044.59N/A
20242024-12-31USD -31,458.30-96.2%
20252025-12-31USD -87.27-99.7%
Aptevo Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3090.4%
Q32025-09-3073.5%
Q42025-12-31-297.0%
Q12026-03-3196.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$35.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$5.12MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$155.20K

N/A

Employees

33

N/A

Net Income

-$6.70M

-4.5%

EBITDA

-$6.66M

-5.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$14.53M

+579.1%

Total Debt

$4.42M

+0.0%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$3.53M

-20.2%

Short Term Debt

$892.00K

N/A

Return on Assets

-1.32%

N/A

Return on Invested Capital

-1.76%

N/A

Free Cash Flow

-$7.97M

-21.1%

Operating Cash Flow

-$7.97M

-21.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BCDABioCardia, Inc.
$0.82+6.89%
RADXRadiopharm Theranostics Limited
$3.15-1.56%
HCWBHCW Biologics Inc.
$3.20+1.59%
ABPAbpro Corporation
$0.52+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About APVO

What is the current price of Aptevo Therapeutics?

Aptevo Therapeutics is trading at $4.11 per share.

What is the 52-week range for Aptevo Therapeutics?

Over the past 52 weeks, Aptevo Therapeutics has traded between $3.68 and $50.40.

How much debt does Aptevo Therapeutics have?

As of the most recent reporting period, Aptevo Therapeutics reported total debt of $4.42M.

How much cash does Aptevo Therapeutics have on hand?

Aptevo Therapeutics reported $14.53M in cash and cash equivalents in its most recent financial results.

What is Aptevo Therapeutics’s dividend yield?

Aptevo Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services